Advanced search
1 file | 990.44 KB

Maintaining the silence: reflections on long-term RNAi

Koen Raemdonck (UGent) , Roosmarijn Vandenbroucke (UGent) , Jo Demeester (UGent) , Niek Sanders (UGent) and Stefaan De Smedt (UGent)
(2008) DRUG DISCOVERY TODAY. 13(21-22). p.917-931
Author
Organization
Abstract
Since the demonstration of RNA interference (RNAi) in mammalian cells, considerable research and financial effort has gone towards implementing RNAi as a viable therapeutic platform. RNAi is, without doubt, the most promising strategy for the treatment of human genetic disorders. Because many of the targets proposed for RNAi therapy require chronic treatment, researchers agree that the emphasis must now be placed on the safe and long-term application of RNAi drugs to reap the benefits at last.
Keywords
MAMMALIAN-CELLS, HUMAN-CELLS, DNA METHYLATION, SMALL INTERFERING RNA, SHORT HAIRPIN RNA, DOUBLE-STRANDED-RNA, IN-VIVO DELIVERY, TRANSMEMBRANE PROTEIN SID-1, INNATE IMMUNE-RESPONSE, HEPATITIS-B-VIRUS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 990.44 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Raemdonck, Koen, Roosmarijn Vandenbroucke, Jo Demeester, Niek Sanders, and Stefaan De Smedt. 2008. “Maintaining the Silence: Reflections on Long-term RNAi.” Drug Discovery Today 13 (21-22): 917–931.
APA
Raemdonck, K., Vandenbroucke, R., Demeester, J., Sanders, N., & De Smedt, S. (2008). Maintaining the silence: reflections on long-term RNAi. DRUG DISCOVERY TODAY, 13(21-22), 917–931.
Vancouver
1.
Raemdonck K, Vandenbroucke R, Demeester J, Sanders N, De Smedt S. Maintaining the silence: reflections on long-term RNAi. DRUG DISCOVERY TODAY. 2008;13(21-22):917–31.
MLA
Raemdonck, Koen, Roosmarijn Vandenbroucke, Jo Demeester, et al. “Maintaining the Silence: Reflections on Long-term RNAi.” DRUG DISCOVERY TODAY 13.21-22 (2008): 917–931. Print.
@article{446726,
  abstract     = {Since the demonstration of RNA interference (RNAi) in mammalian cells, considerable research and financial effort has gone towards implementing RNAi as a viable therapeutic platform. RNAi is, without doubt, the most promising strategy for the treatment of human genetic disorders. Because many of the targets proposed for RNAi therapy require chronic treatment, researchers agree that the emphasis must now be placed on the safe and long-term application of RNAi drugs to reap the benefits at last.},
  author       = {Raemdonck, Koen and Vandenbroucke, Roosmarijn and Demeester, Jo and Sanders, Niek and De Smedt, Stefaan},
  issn         = {1359-6446},
  journal      = {DRUG DISCOVERY TODAY},
  keyword      = {MAMMALIAN-CELLS,HUMAN-CELLS,DNA METHYLATION,SMALL INTERFERING RNA,SHORT HAIRPIN RNA,DOUBLE-STRANDED-RNA,IN-VIVO DELIVERY,TRANSMEMBRANE PROTEIN SID-1,INNATE IMMUNE-RESPONSE,HEPATITIS-B-VIRUS},
  language     = {eng},
  number       = {21-22},
  pages        = {917--931},
  title        = {Maintaining the silence: reflections on long-term RNAi},
  url          = {http://dx.doi.org/10.1016/j.drudis.2008.06.008},
  volume       = {13},
  year         = {2008},
}

Altmetric
View in Altmetric
Web of Science
Times cited: